Predictive Value of Diminished Serum PDGF-BB after Curative Resection of Hepatocellular Cancer
Table 1
Demographics and clinical and pathological data of the cohort.
Variables
Data
Age, median (min, max)
72.52 (51, 83)
Sex, n (%)
Male,
30 (75 %)
Female
10 (25 %)
Child Pugh Class, n (%)
A
40 (100 %)
B
0
C
0
Etiology, n (%)
HBV
12 (30 %)
HCV
13 (32.5 %)
Nonviral
15 (37.5 %)
Fibrosis grade, n (%)
0-2
22 (55 %)
3-4
18 (45 %)
Tumor staging, n (%)
I-II
28 (70 %)
III-IV
12 (30 %)
Tumor size, n (%)
< 5 cm
27 (67.5 %)
≥ 5 cm
13 (32.5 %)
Tumor number, n (%)
Single
31 (77.5 %)
Multiple
09 (22.5 %)
Vascular invasion, n (%)
Present
08 (20 %)
Absent
32 (80 %)
Tumor histology (differentiation), n (%)
Well-to-moderate
32 (80 %)
Poor
08 (20 %)
Type of hepatectomy, n (%)
Major hepatectomy
14 (35 %)
Minor hepatectomy
26 (65 %)
Prior treatment, n (%)
RFA/TACE
19 (47.5 %)
None
21 (52. 5 %)
Total bilirubin before resection, n (%)
< 1 mg/dl
28 (70 %)
≥ 1 mg/dl
12 (30 %)
INR before resection, n (%)
> 1
30 (75 %)
< 1
10 (25 %)
AFP before resection, n (%)
< 20 ng/ml
25 (62.5 %)
≥ 20 ng/ml
15 (37.5 %)
Clavien-Dindo postoperative (severe) morbidity, n (%)
Absent
35 (87.5 %)
Present
05 (12.5 %)
Min., minimum; max., maximum; n/N, numbers; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio, AFP, alpha-fetoprotein; PIVKA II, protein induced by vitamin K absence/antagonist-II; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; INR, international normalized ratio.
